VISTAGEN THERAPEUTICS, INC. Proceeds from Debt, Net of Issuance Costs
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Proceeds from Debt, Net of Issuance Costs of $119.00 million for the 12-month period ending 2021-03-31, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2021-08-12
| Period end | Proceeds from Debt, Net of Issuance Costs 1 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|
| 2021-03-31 | $119.00M 10-Q · filed 2021-08-12 | |
| 2020-08-31 | $4.66M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |